All of WSIPP's research is published on our website. The Publications page includes every report we've released—from our founding in 1983 to the present. Each report entry includes the title, publication date, abstract, any available supplemental materials, and a downloadable PDF.
WSIPP reports are not updated after publication, and any report older than two years is designated with an “Archived” label.
To explore our benefit-cost and meta-analytic findings, please visit the Benefit-Cost section of the website.
Use the search fields below to find specific publications that match certain criteria. If you want to find other information on our website that is not publications, you can use the search field in the navigation bar at the top, or click here to search the entire website.
Found 1 results
In November 2012, Washington State voters passed Initiative 502 (I-502), which legalized limited possession, private use, and commercial sales of cannabis for adults. In this study, we explore the relationship between licensed cannabis retail availability in Washington State and healthcare outcomes related to cannabis use disorder (CUD) and mental health disorders, including depression, anxiety, bipolar, and psychotic disorders.
Using claims and encounter data on Medicaid enrollees aged 12-64, we find that residence near a cannabis retailer predicts higher rates of CUD, CUD-related hospitalization, and CUD-related inpatient SUD treatment. Furthermore, we find that living near a retailer predicts higher rates of co-occurring CUD and mental health disorder diagnoses. Last, we find that living near a retailer is associated with an increase in the probability of having a mental health disorder diagnosis following a CUD diagnosis. Evidence suggests that impacts are generally largest in neighborhoods with multiple active retailers nearby.